Burden of Hereditary Angioedema in Adults: Impact of Disease and Patient Characteristics Authors: Maureen Watt, Inmaculada Martinez Saguer, Ryan Murphy, Marie De La Cruz, Ricardo Zwiener, Mauricio Sarrazola, Anete S. Grumach Published: 2026 ABSTRACT AbstractIntroductionHereditary angioedema (HAE) has a heterogeneous clinical presentation, and symptoms can vary in severity and frequency. The aim of this post hoc analysis was to describe the burden of disease in patients with HAE according to the impact of the disease and patient characteristics.MethodsA cross-sectional, web-based survey in 13 countries was conducted to assess the burden of disease in patients aged ≥18 years with HAE. This post hoc analysis assessed disease control, HRQoL, anxiety, depression, and work productivity by subgroups defined by sex, perception of disease control and HRQoL impairment. Patient-reported outcomes included the Angioedema Quality of Life (AE-QoL), Angioedema Control Test (AECT), Hospital Anxiety and Depression Scale (HADS), and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaires. Descriptive statistics were used to describe the results by subgroups.ResultsOf 260 respondents (189 female; 71 male) who completed the survey, 195/260 (75.0%) perceived their HAE was poorly controlled (AECT score <10) and 137/260 (52.7%) had moderate-to-large HRQoL impairment (AE-QoL score ≥39). Relative to male respondents, females reported higher HRQoL impairment (AE-QoL total score mean ± SD 46.5 ± 23.3 vs. 33.3 ± 20.1), a perception of more poorly controlled disease (AECT score 7.1 ± 3.0 vs. 8.3 ± 3.0), and a higher proportion reported moderate or severe anxiety (33.9% vs. 7.0%) and depression (12.2% vs. 5.6%) according to the HADS. Respondents who perceived their HAE was poorly controlled had a higher number of HAE attacks in the last 6 months, reported greater HRQoL impairment, higher scores on HADS anxiety and depression subscales, and greater WPAI:GH work and activity impairment than those who perceived their HAE to be well controlled (AECT ≥10). Similarly, patients reporting moderate-to-large HRQoL impairment reported more HAE attacks in the last 6 months, higher scores on HADS anxiety and depression subscales, and greater WPAI:GH work and activity impairment than those with an AE-QoL score <39.ConclusionIn this post hoc analysis, the burden of HAE was consistently higher in females than males, in respondents who reported their disease to be poorly controlled versus well-controlled, and in those with moderate-to-large versus minimal HRQoL impairment. Findings support the use of patient-reported outcomes to assess burden of disease in routine clinical practice to understand the broader burden of disease beyond metrics such as attack rate and to consider individual circumstances and experiences. Introduction Hereditary angioedema (HAE) is a rare disease most frequently associated with a deficiency or dysfunction of C1 inhibitor (C1INH), termed HAE-C1INH-Type1 or Type2, respectively, clinically characterized by painful, recurrent attacks of edema [1, 2]. Although there are recognized triggers, attacks are often unpredictable. However, there is a known influence of stress and gender-based hormones on the timing and severity of attacks, and anxiety is a known attack trigger. Notably, HAE attacks in female patients have been reported to be more frequent and/or severe compared with HAE attacks in male patients [3]. This may be due to the effect of estrogen (including ovulation, menstruation, and pregnancy), which can complicate female-specific care during pregnancy, labor and delivery, lactation, and menopause [4]. Patients with HAE often have a high level of health-related quality of life (HRQoL) impairment. The burden of disease can affect patients’ activities of daily living, work productivity, and psychological well-being with many patients reporting anxiety and depression, sleep disturbances, fear of future attacks, and guilt related to absence from work, school, or other social activities [5–12]. Improving HRQoL has become a predominant goal in HAE management, specifically mentioned in clinical guidelines, which can be improved through the use of long-term prophylaxis (LTP), and patients should have individualized management plans to lessen the burden of disease and improve HRQoL [1, 6, 13]. HRQoL impairment in patients with HAE depends not only on the frequency and severity of HAE attacks, both of which are variable among different patients and over time in the same patient [2, 14, 15], but also on disease burden between attacks such as interference with educational or career enhancement and/or lifestyle modifications to avoid triggers [16]. Subsequently, the degree of HRQoL impairment may vary considerably among patients with HAE. Similarly, HAE attack frequency and severity as well as the pharmacological management of HAE attacks can have an impact on patient perception of disease control and may lead to variation in disease control levels among patients. A large multinational survey in 13 countries that aimed to understand the burden of disease in adult patients with HAE found that despite the majority of patients being on treatment for HAE, albeit not modern first-line recommended treatments in most cases, patients reported a considerable burden of disease, demonstrating an unmet need [17]. The study successfully recruited the largest cohort of adult patients with HAE to date to a patient survey assessing burden of disease, and the substantial sample size (not often achieved in a rare disease) provided an opportunity to conduct in-depth analyses into specific subgroups of interest, which was previously challenging due to limited data availability. These insights have the potential to advance understanding of disease burden in these patient subgroups and improve quality of care. The aim of this post hoc analysis was to describe the burden of disease in key patient cohorts with HAE, with a particular focus on the level of disease control, HRQoL impairment, anxiety, depression, and impact on work productivity. Methods Study Design and Population The methodology for this noninterventional, cross-sectional, web-based survey has been published previously [17]. Briefly, the survey was conducted from July 2022 through February 2023 in 13 countries across Europe and South America (Argentina, Brazil, Colombia, Croatia, Denmark, Germany, Hungary, Ireland, Norway, Poland, Portugal, Romania, and Sweden) and was translated into the official language of each country. Patients were aged ≥18 years and had a self-reported physician diagnosis of HAE. Before recruitment and data collection, Institutional Review Board/Ethics Committee approval was obtained for each site and/or country, and all survey respondents provided informed consent. The study was conducted in accordance with the protocol, the Declaration of Helsinki, Good Pharmacoepidemiology Practices, International Society of Pharmacoepidemiology guidelines for Good Pharmacoepidemiology Practices, and local regulations. Study Assessments The patient-reported outcome measures (PROMs) included the Angioedema Quality of Life questionnaire (AE-QoL) [18–20], the Angioedema Control Test (AECT) [21, 22], the Hospital Anxiety and Depression scale (HADS) [23], and the Work Productivity and Activity Impairment: Global Health (WPAI:GH) questionnaire [24, 25]. The PROMs used in the survey have been described in detail previously [17]. Briefly, the AE-QoL is a validated, disease-specific instrument assessing HRQoL impairment over the last 4 weeks in patients with recurrent angioedema [19, 20]. The AE-QoL has 17 questions used to calculate total and domain (Functioning, Fatigue/Mood, Fears/Shame, and Nutrition) scores (range: 0–100), with higher scores representing greater HRQoL impairment [19]. The validated minimal clinically important difference was defined as a 6-point difference in the AE-QoL total score [20]. AE-QoL total scores of 0–38 and ≥39 indicate no-to-small and moderate-to-large HRQoL impairment, respectively [18]. The AECT is a validated, disease-specific instrument assessing disease control in patients with recurrent angioedema [21, 22]. This study used the version of the AECT with a 3-month recall period. AECT scores range 0–16, with scores of <10 and ≥10 indicating poorly controlled and well-controlled disease, respectively [22]. The HADS is a generic measure assessing anxiety and depression in the past week [23]. HADS anxiety and depression subscale scores range 0–21, with scores of 8–10, 11–14 and 15–21 indicating mild, moderate, and severe anxiety/depression, respectively [26]. The WPAI:GH is a generic measure assessing productivity loss related to health during the past 7 days [24, 25]. WPAI:GH scores are expressed as percentages of absenteeism (work time missed), presenteeism (reduced productivity while working), overall work productivity loss (combined absenteeism and presenteeism), and activity loss (impairment in daily activities not related to work) [24]. Statistical Analyses Patient subgroups investigated in this analysis included well-controlled and poorly controlled disease (AECT score of ≥10 and <10, respectively), post hoc analyses of subgroups according to sex (male and female), and no-to-small and moderate-to-large HRQoL impairment (AE-QoL total score of <39 and ≥39, respectively). The AECT is a relatively new measure (2020), so use of this PROM tool in this study provides more context on the burden of HAE in patients who perceive their disease to be poorly or well controlled. The AE-QoL threshold has also been recently defined (2019), and inclusion of these subgroups in this post hoc analysis provides greater context to the humanistic experience of patients with moderate-to-large HRQoL impairment. PROMs were also assessed among respondents who had a diagnosis of HAE-nC1INH (HAE with normal C1INH) and those who had a diagnosis of HAE-C1INH-Type1/Type2 or unknown HAE-C1INH type. Descriptive statistics were used to describe the results, using mean ± SD for continuous variables and numbers and percentages for categorical variables. Because recall periods differ across the different PROM tools used in this study, cross-instrumental contrasts are descriptive and not intended to imply temporal relationships. Results The overall demographic and clinical characteristics of the 260 respondents who completed the survey have been described previously [17]. Males and Females Of the 260 respondents included, 189 respondents were female and 71 were male. Respondent demographics when subgroups were categorized by sex are shown in Table 1. Although age of HAE onset was similar between female and male respondents, female respondents reported, on average, a longer time to diagnosis of approximately 4 years compared with male respondents. Table 1.Patient demographic and clinical characteristics by subgroups​SexAECT scoreAE-QoL scoremale (n = 71)female (n = 189)score <10 (poorly controlled disease: n = 195)score ≥10 (well-controlled disease; n = 65)total score <39 (no-to-small HRQoL impairment; n = 123)total score ≥39 (moderate-to-large HRQoL impairment; n = 137)Age, years Mean±SD42.0±13.843.7±13.443.1±13.243.7±14.444.4±13.642.3±13.4 Range18.0–73.018.0–81.018.0–75.018.0–81.018.0–81.018.0–75.0Sex, n (%) Female0189 (100)147 (75.4)42 (64.6)77 (62.6)112 (81.8) Male71 (100)048 (24.6)23 (35.4)46 (37.4)25 (18.2)HAE type, n (%) HAE-C1INHa69 (97.2)164 (86.8)173 (88.7)60 (92.3)116 (94.3)117 (85.4) HAE-nC1INH015 (7.9)12 (6.2)3 (4.6)3 (2.4)12 (8.8) Unknownb2 (2.8)10 (5.3)10 (5.1)2 (3.1)4 (3.3)8 (5.8)Age at HAE onset, years, mean±SD11.9±9.112.1±8.912.4±9.410.9±7.312.2±8.311.9±9.5Age at HAE diagnosis, years, mean±SD21.0±13.225.3±13.624.9±13.421.8±14.122.7±13.925.5±13.2Family history of HAE, n (%) Yes56 (78.9)148 (78.3)149 (76.4)55 (84.6)98 (79.7)106 (77.4) No13 (18.3)31 (16.4)36 (18.5)8 (12.3)20 (16.3)24 (17.5) Not sure2 (2.8)10 (5.3)10 (5.1)2 (3.1)5 (4.1)7 (5.1)HAE attacks in the past 6 months, mean±SD9.8±13.612.1±14.413.9±15.04.2±8.07.8±10.014.8±16.5AECT score, mean±SD8.3±3.07.1±3.06.1±2.211.4±1.39.3±2.55.7±2.5Current medication used for LTP,cn/N (%) Any46/71 (64.8)107/189 (56.6)104/195 (53.3)49/65 (75.4)83/123 (67.5)70/137 (51.1) Androgens Danazol14/46 (30.4)20/107 (18.7)21/104 (20.2)13/49 (26.5)19/83 (22.9)15/70 (21.4) Oxandrolone6/46 (13.0)17/107 (15.9)17/104 (16.3)6/49 (12.2)11/83 (13.3)12/70 (17.1) C1INH Human C1INH (Berinert)7/46 (15.2)17/107 (15.9)16/104 (15.4)8/49 (16.3)13/83 (15.7)11/70 (15.7) Human C1INH (Cinryze)01/107 (0.9)1/104 (1.0)001/70 (1.4) Lanadelumab9/46 (19.6)15/107 (14.0)13/104 (12.5)11/49 (22.4)17/83 (20.5)7/70 (10.0) Tranexamic acid4/46 (8.7)17/107 (15.9)15/104 (14.4)6/49 (12.2)8/83 (9.6)13/70 (18.6) Berotralstat1/46 (2.2)9/107 (8.4)8/104 (7.7)2/49 (4.1)6/83 (7.2)4/70 (5.7) Other12/46 (26.1)18/107 (16.8)22/104 (21.2)8/49 (16.3)16/83 (19.3)14/70 (20.0) Missingd25/71 (35.2)82/189 (43.4)91/195 (46.7)16/65 (24.6)40/123 (32.5)67/137 (48.9)AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life questionnaire; C1INH, C1 inhibitor; HAE, hereditary angioedema; HRQoL, health-related quality of life; LTP, long-term prophylaxis; HAE-nC1INH, hereditary angioedema due to normal C1 inhibitor. aRespondents who answered, “HAE Type I,” “HAE Type II, or “Unsure of exact HAE type, but it is either HAE Type I or II” to the survey question “Which type of HAE do you have?” bRespondents who answered. “I don’t know what type of HAE” to the survey question “Which type of HAE do you have?” cRespondents could select more than 1 response (categories nonexclusive) and may be counted in more than 1 category. dNo response was given to the survey question on current LTP medication. Patient demographic and clinical characteristics by subgroups AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life questionnaire; C1INH, C1 inhibitor; HAE, hereditary angioedema; HRQoL, health-related quality of life; LTP, long-term prophylaxis; HAE-nC1INH, hereditary angioedema due to normal C1 inhibitor. aRespondents who answered, “HAE Type I,” “HAE Type II, or “Unsure of exact HAE type, but it is either HAE Type I or II” to the survey question “Which type of HAE do you have?” bRespondents who answered. “I don’t know what type of HAE” to the survey question “Which type of HAE do you have?” cRespondents could select more than 1 response (categories nonexclusive) and may be counted in more than 1 category. dNo response was given to the survey question on current LTP medication. The AE-QoL total score (mean ± SD) was numerically higher in female (46.5 ± 23.3) versus male (33.3 ± 20.1) respondents, with the difference exceeding the 6-point threshold for minimal clinically important difference (Fig. 1a). A mean AE-QoL total score of ≥39 was found only in the female subgroup, which is reflective of moderate-to-large HRQoL impairment. Female respondents also had numerically higher scores across all AE-QoL domains than male respondents (Fig. 1a). AE-QoL scores by sex (a), AECT category (b), and AE-QoL category (c). The AE-QoL questionnaire is a disease specific, validated measure for patients with recurrent angioedema that assesses HRQoL impairment, which consists of 17 questions across 4 domains (Functioning, 4 questions; Fatigue/Mood, 5 questions; Fears/Shame, 6 questions; Nutrition, 2 questions) and a total score over a recall period of “over the past 4 weeks” [19]. Domain and total scores have a range of 0–100, with higher scores indicating greater HRQoL impairment [19]. AE-total scores of 0–23, 24–38, and ≥39 have been proposed to indicate no effect, small effect, and moderate-to-large effect of recurrent angioedema on HRQoL [18]. A 6-point difference in AE-QoL total score has been validated as the minimal clinically important difference [20]. AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life; HRQoL, health-related quality of life. Although both sexes perceived their HAE as poorly controlled (AECT score <10), female respondents had a numerically lower AECT score (mean ± SD) compared with male respondents (7.1 ± 3.0 vs. 8.3 ± 3.0). Both HADS anxiety and depression subscale scores were also numerically higher in female versus male respondents (Fig. 2a). The mean HADS anxiety subscale score in female respondents was 8.6 points, meeting the criteria for mild anxiety, while the mean HADS anxiety subscale score in male respondents was 5.2, reflective of normal levels of anxiety. Additionally, higher proportions of female versus male respondents reported moderate or severe anxiety (33.9% vs. 7.0%) and moderate or severe depression (12.2% vs. 5.6%; Fig. 3). WPAI:GH scores across the domains of presenteeism, overall work productivity loss, and activity impairment were also numerically higher in female than male respondents, although male respondents had numerically slightly higher WPAI:GH absenteeism scores (Fig. 4a). HADS scores by sex (a), AECT category (b), and AE-QoL category (c). HADS is a generic measure to assess anxiety and depression consisting of 14 questions (7 each for anxiety and depression) over a recall period of “in the past week” [23]. HADS anxiety and depression subscales range from 0 to 21, with higher scores indicating greater impairment [23]. Subscale scores of 0–7, 8–10, 11–14, and 15–21 indicate normal levels of anxiety or depression, mild anxiety or depression, moderate anxiety or depression, and severe anxiety and depression, respectively [23, 26]. Subscale scores can be summed to yield a total score reflecting psychological distress, scored from 0 to 42 [27]. AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life; HADS, Hospital Anxiety and Depression Scale. HADS anxiety (a) and depression (b) categories by sex. HADS is a generic measure to assess anxiety and depression consisting of 14 questions (7 each for anxiety and depression) over a recall period of “in the past week” [23]. HADS anxiety and depression subscales range from 0 to 21, with higher scores indicating greater impairment [23]. Subscale scores of 0–7, 8–10, 11–14, and 15–21 indicate normal levels of anxiety or depression, mild anxiety or depression, moderate anxiety or depression, and severe anxiety and depression, respectively [23, 26]. Subscale scores can be summed to yield a total score reflecting psychological distress, scored from 0 to 42 [27]. HADS, Hospital Anxiety and Depression Scale. WPAI:GH scores by sex (a), AECT category (b), and AE-QoL category (c). WPAI:GH is a generic measure to assess health-related work productivity loss consisting of 6 questions over a recall period of “during the past 7 days” [24, 25]. WPAI:GH consists of 4 domains (absenteeism [work time missed], presenteeism [reduced productivity while working] overall work productivity loss [combined absenteeism and presenteeism], and activity impairment [impairment in daily activities not related to work]. Each domain score is expressed as a percentage of productivity loss/impairment, where higher scores indicate a greater loss in productivity [24]. AECT, Angioedema Control Test; AE-QoL, Angioedema Quality of Life; HRQoL, health-related quality of life; WPAI:GH, Work Productivity and Activity Impairment: Global Health. AECT Subgroups Most respondents (n = 195; 75.0%) reported that they perceived their angioedema as being poorly controlled (AECT score <10) while the remainder (n = 65; 25.0%) reported perceiving their angioedema as well controlled (AECT score ≥10). Respondents with poorly controlled HAE (AECT <10) had a numerically higher number of attacks in the last 6 months compared with respondents with well controlled HAE (Table 1). A numerically lower proportion of respondents with poorly controlled HAE were receiving LTP (53.3%) than respondents who perceived their HAE to be well-controlled (75.4%), although the majority of respondents in both groups were not receiving recommended modern first-line treatments. As might be expected, respondents perceiving they had poorly controlled HAE had greater HRQoL impairment compared with respondents with well-controlled disease, as shown by numerically higher AE-QoL total and domain scores (Fig. 1b). Moderate-to-large impairment in HRQoL (AE-QoL total score of ≥39) was reported by respondents with poorly controlled HAE but not by those who perceived their HAE to be well-controlled. A greater proportion of respondents with poorly versus well-controlled disease also had higher levels of HADS anxiety and depression (Fig. 2b), and WPAI:GH scores were numerically higher across all domains in respondents who reported poorly versus well-controlled disease (Fig. 4b). Additionally, patients who reported poorly controlled disease reported that a higher proportion of their working hours were negatively impacted by their HAE compared to patients who reported well-controlled disease (33.4% ± 34.0% [mean ± SD] vs. 8.0% ± 15.5%). AE-QoL Subgroups Respondent demographics when subgroups were categorized by AE-QoL total score of <39 or ≥39 are shown in Table 1. Respondents with an AE-QoL total score of ≥39 had greater HRQoL impairment across all AE-QoL domains compared with those with an AE-QoL total score of <39 (Fig. 1c). HADS anxiety and depression subscale scores were numerically higher in respondents with an AE-QoL total score of ≥39 versus <39 (Fig. 2c), and WPAI:GH scores were numerically higher across all domains in respondents with an AE-QoL total score ≥39 versus <39 (Fig. 4c), indicating greater HRQoL impairment across these measures. Respondents with a total AE-QoL score of ≥39 had a higher mean ± SD number of attacks in the past 6 months (14.8 ± 16.5) than those with a total AE-QoL score of <39 (7.8 ± 10.0). A higher proportion of respondents with moderate-to-large HRQoL impairment reported that their most recent attack was severe or very severe (39.3%) than those with no-to-small HRQoL impairment (21.3%). The location of the most recent attack by AE-QoL subgroups that affected ≥5% of respondents in the sample as a whole is shown in Table 2. The most commonly affected location during an HAE attack was the abdomen for respondents with no-to-small and moderate-to-large HRQoL impairment. More respondents with moderate-to-large HRQoL impairment reported that their most recent attack affected the throat or larynx than those with no-to-small HRQoL impairment. Table 2.Location of the most recent attack by AE-QoL subgroups that occurred in ≥5% of the sample as a wholeLocation<39 (no-to-small HRQoL impairment; n = 123)≥39 (moderate-to-large HRQoL impairment; n = 137)Arms (including the joints)15 (12.2)30 (21.9)Legs (including the joints)16 (13.0)30 (21.9)Hands28 (22.8)31 (22.6)Feet32 (26.0)31 (22.6)Lips4 (3.3)13 (9.5)Eyes4 (3.3)10 (7.3)Throat or larynx4 (3.3)16 (11.7)Back4 (3.3)13 (9.5)Buttocks9 (7.3)16 (11.7)Abdomen (stomach)57 (46.3)70 (51.1)Genitals8 (6.5)30 (21.9)Bladder6 (4.9)16 (11.7)Bowels or rectum12 (9.8)30 (21.9)Values are n (%). AE-QoL, Angioedema Quality of Life questionnaire; HRQoL, health-related quality of life. Location of the most recent attack by AE-QoL subgroups that occurred in ≥5% of the sample as a whole Values are n (%). AE-QoL, Angioedema Quality of Life questionnaire; HRQoL, health-related quality of life. HAE Type Although a small group, respondents with a diagnosis of HAE-nC1INH had numerically lower mean ± SD AECT scores (n = 15; 7.1 ± 3.0) than respondents with HAE-C1INH-Type1/Type2 (n = 233; 7.4 ± 3.1) or with unknown HAE-C1INH type (n = 12; 7.3 ± 2.9). Respondents with HAE-nC1INH reported greater HRQoL impairment than those with HAE-C1INH-Type1/Type2 or unknown HAE-C1INH type shown by higher AE-QoL domain and total scores (online suppl. Fig. 1A; for all online suppl. material, see https://doi.org/10.1159/000551657). Respondents with HAE-nC1INH also reported higher HADS anxiety and depression scores than those with HAE-C1INH-Type1/Type2 or unknown HAE-C1INH type (online suppl. Fig. 1B), along with higher levels of WPAI:GH presenteeism, overall work productivity loss, and activity impairment (online suppl. Fig. 1C). Discussion Here, we report the subgroup analysis findings of a cross-sectional survey of patients with HAE conducted in 13 countries that generated the largest dataset of disease burden in this chronic condition. This analysis focused on the subgroups categorized by sex and PROMs with well-established thresholds indicating high vs. low HRQoL impairment (AE-QoL) and poor vs. well-controlled disease (AECT). Overall, the disease burden as assessed by HRQoL impairment (AE-QoL), perception of disease control (AECT), anxiety/depression (HADS), and work productivity loss (WPAI:GH) was consistently higher in female vs. male respondents, in those who perceived that their HAE was poorly vs. well controlled, and in respondents with moderate-to-large vs. no-to-small HRQoL impairment. Although HAE is known to affect both sexes equally [4], female respondents with HAE reported a greater disease burden compared with male respondents, including numerically higher rates of HAE attacks and longer delays to diagnosis. Female versus male respondents also had higher HRQoL impairment as measured by AE-QoL and higher rates of moderate-to-severe anxiety and depression. Although the proportion of respondents reporting LTP use was more than half in both sexes, it was numerically lower in female versus male respondents, suggesting that the use of LTP may have contributed to the smaller burden of disease in male patients. However, it should be noted that the majority of patients were not receiving modern first-line LTP options such as lanadelumab or berotralstat. Our findings add to the limited data on the experience of female patients with HAE in comparison to male patients, and to the growing literature reporting that female patients may experience chronic conditions differently from males regardless of country-specific cultural experiences [28]. For example, a validation study of the Japanese version of the AE-QoL found that female patients had significantly higher mean scores than male patients (42.2 ± 25.7 vs. 23.8 ± 17.5) [29]. A further validation of the AE-QoL among Latvian patients found a significantly higher median total score in female than male patients (47.8 vs. 14.7, p < 0.001), and higher AE-QoL domain scores were also observed in female patients [30]. Additionally, in a single center cohort of Canadian patients with HAE, female patients had significantly higher scores for the AE-QoL domain of Fears/Shame than male patients [31]. Further research to better understand the experience of female patients with HAE is of importance, particularly given that increased serum estrogen levels are associated with an increased frequency of HAE attacks and that menstruation and ovulation have been found to trigger attacks [4]. Furthermore, estrogen-containing oral contraceptives and hormone replacement therapy during menopause have also been identified as triggers of attacks [4, 32]. This survey did not capture data on contraceptive use or hormone replacement therapy, and further assessments of female patients with HAE receiving hormone therapy would be a valuable area for future study. Furthermore, this survey did not capture differences in caregiver status between female and male respondents and whether associated responsibilities might be a contributing factor to the greater impairment observed in female respondents. Finally, observed differences in disease control by sex may have been influenced by unmeasured factors such as comorbidities, socioeconomic status, access to care, treatment availability, and country-specific healthcare differences which warrant further investigation. The impairment in HRQoL in relation to perceptions of disease control observed in this survey are in line with those from studies reporting the correlation between the AE-QoL and AECT. For example, a study assessing the minimally clinically important difference of the AECT reported a significant negative correlation with the AE-QoL (−0.60; p < 0.001) [33], while a similar negative correlation was also observed in a validation study of the Chinese versions of the AE-QoL and AECT (−0.456; p < 0.05) [34]. A similar pattern has also been observed in studies evaluating the outcomes of LTP treatment. For example, in the phase 3 OASIS-HAE donidalorsen study, well-controlled and poorly controlled disease subgroups as defined by the AECT had significantly different mean AE-QoL scores (p < 0.001) [35]. Similarly, in the lanadelumab HELP OLE study, in both rollover and newly enrolled patients, those with well-controlled disease as defined by the AECT had lower mean AE-QoL scores than those with poorly controlled disease at the end of the study [36]. This result is consistent with our survey, which reports that patients who perceived their disease to be poorly controlled had an AE-QoL total score (mean ± SD) above the threshold of 39 points (50.0 ± 21.4), indicating moderate-to-large impairment on HRQoL, while those reporting well-controlled disease were below this threshold (21.6 ± 13.4), indicating no-to-small HRQoL impairment. The majority of data reporting quality of life in patients with HAE focuses on patients with a diagnosis of HAE-C1INH-Type1/Type2, and data on patients with HAE-nC1INH are limited. While a diagnosis of HAE-nC1INH is rarer than that of HAE-C1INH-Type1/Type2 [37], a recent study of 30 HAE-treating physicians from accredited Angioedema Centers of Reference and Excellence in 15 countries estimated that in all patients with HAE, 24% (range 2%–44%) were diagnosed with HAE-nC1INH, suggesting it may be more prevalent than previously considered [38]. It is, therefore, important to understand patient experiences in this subgroup. In this analysis, 15/260 patients (5.8%) reported a diagnosis of HAE-nC1INH and also reported greater HRQoL impairment, higher HADS anxiety and depression scores, and greater WPAI:GH impairment than patients with a diagnosis of HAE-C1INH-Type1/Type2 or unknown type. These findings add to the limited data on patients with a diagnosis of HAE-nC1INH and suggest that this subgroup may experience a greater burden of disease, which in part may be due to the absence of specific treatments for HAE-nC1INH [39]. Given the variable and severe nature of HAE and the associated disease burden for patients, optimal treatment plans for patients need to consider a range of factors, including attack severity, attack frequency, burden of disease, and disease control [16]. Given that one of the primary goals of therapeutic management with LTP is to reduce the overall burden of disease, patient HRQoL should also be assessed alongside attack frequency and severity during longitudinal patient follow-up [1] by routine use of PROMs such as the AE-QoL. In addition to HRQoL, patient perception of disease control is an important consideration in order to guide treatment decisions and monitor patient response to particular LTPs [16]. The AECT offers a brief and simple measure of a patient’s perception of how well their HAE is controlled. Therefore, as part of a multifaceted, holistic approach to individualized patient care, a range of PROMs should be routinely incorporated into clinical practice to help inform the need for and use of first-line LTPs. The WAO/EAACI (2021) guidelines recommend the use of plasma-derived C1 inhibitor, lanadelumab, or berotralstat as first-line LTP treatments, while androgens are recommended only as second-line treatment [1]. Most patients in this survey did not receive these modern first-line LTP treatments with the majority of patients who took LTP treatment receiving androgens. Since 54% of patients in this study had been taking LTP for ≥3 years, the low levels of newer agents may reflect limited access at the time of the study relative to the country-specific reimbursements. A recent Delphi consensus document provides useful guidance on the monitoring, gradual discontinuation, and substitution of androgen therapy given the wider availability of first-line options [40]. While this analysis provided a greater level of granularity about the findings from a large multicenter study on the burden of disease for adult patients with HAE, potential limitations should be considered when interpreting these results. Given the cross-sectional study design, no baseline or follow-up visits were scheduled; therefore, it was not possible to assess the disease burden over time precluding causal inferences. Furthermore, the cross-sectional design and absence of baseline and follow-up measures precluded unbiased, valid analyses of subgroups categorized according to treatment with and without LTP or categorized by type of LTP; such analyses require longitudinal data and an assessment of change for their interpretation rather than a single point-in-time assessment. Additionally, cross-sectional surveys are prone to confounding variables on which data are not collected, such as certain demographics, disease progression, concurrent medications, and environmental factors. Finally, all data were self-reported by patients and thus have the potential for recall bias. Conclusions These subgroup analyses of a multinational survey of patients who were largely not receiving a first-line LTP identified some features of patients with HAE who may experience especially high disease burden. Disease burden was greater in female versus male respondents and those who reported higher HRQoL impairment, a perception of more poorly controlled disease, and higher rates of moderate or severe anxiety and depression. Disease burden was also greater in respondents who perceived their HAE to be poorly controlled versus well-controlled and in respondents with moderate-to-large versus minimal HRQoL impairment. These descriptive findings reinforce the use of PROMs in clinical practice to gain a holistic perspective on the burden of disease and to help inform optimal management strategies. Acknowledgments We thank the patients who participated in the survey and the members of the survey team. We also thank Angela Simon, of Takeda Development Center Americas, Inc., for her contribution to the survey. Under the direction of the authors, Jon Waldron, PhD, of Envision Catalyst, an Envision Medical Communications agency, a part of Envision Pharma Group, provided medical writing assistance for this manuscript. The interpretation of the data was made by the authors independently. Statement of Ethics Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approval was obtained before recruitment and data collection for each site or country (both central and local ethics committee approval was required in Brazil, Croatia, and Germany). This study was conducted in accordance with the protocol, the Declaration of Helsinki, Good Pharmacoepidemiology Practices, International Society of Pharmacoepidemiology guidelines for Good Pharmacoepidemiology Practices, and local regulations. Patients provided written informed consent before completing the survey; informed consent was collected electronically in all countries except Colombia, where paper informed consent forms with wet ink signatures were requested by the local regulatory authorities. Approval was provided by the following IRBs/IECs: Comite de Etica en lnvestigaci6n (CIE) Facultad de Ciencias Biomedicas – Universidad Austral (Argentina, 5 May 2022); Centro Universitario FMABC (Brazil, 10 August 2022); Clinica San Jose (Colombia, 30 July 2022); Ethics Committee of Sibenik-Knin County General Hospital 01-9738/1-22 (Croatia, 23 May 2022); Ethik-Kommission bei der Landesärztekammer Hessen V/1/sja/bab/ewa2022-3022-evBO (Germany, 7 November 2022); National Institute of Pharmacy and Food Hygeine OGYÉI/25068-5/2022 (Hungary, 22 June 2022); Tallaght University Hospital 1067 (Ireland, 5 September 2022); Regionale Komiteer for Medisinsk og Helsefaglig Forskningsetikk 262566 (Norway, 10 December 2022); Wojskowa Izba Lekarska 22/22 (Poland, 22 April 2022); Ethics Committee of CHULN and CAML (Portugal, 5 July 2022); Academy of Medical Sciences – National Bioethics Committee for Medicines and Medical Devices 18SNI Registration No: 3782 (Romania, 21 July 2022); Stockholm Department 2 Medicine 2022-03725-01-316155 (Sweden, 10 November 2022). Conflict of Interest Statement M.W. is an employee of Takeda Development Center Americas, Inc., and holds stock/options in Takeda Pharmaceutical Company Limited. I.M.-S. has received research funding support and/or speaker/consultant fees from BioCryst, CSL Behring, KalVista Pharmaceuticals, Octapharma, Pharming, Pharvaris, and Takeda/Shire. R.M. and M.D.L.C. are employees of ICON, which was contracted by Takeda to perform this study. R.Z. reports being a speaker for CSL Behring, Novartis, Pint Pharma, Sanofi, and Takeda; an advisor for AbbVie, CSL Behring, KalVista Pharmaceuticals, Pint Pharma, and Takeda; and a researcher for Sanofi and Takeda. M.S. was contracted by Takeda to conduct this study. A.S.G. has received speaker/consultancy fees from AstraZeneca, Astria, Catalyst, CSL Behring, KalVista Pharmaceuticals, Multicare Pharma, Pharvaris, Pint Pharma, and Takeda; a scholarship from the Brazilian Council of Research (CNPq); and a grant of researcher initiative from Takeda. Funding Sources This survey was sponsored by Takeda Development Center Americas, Inc. The study’s sponsor was involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; formed part of the author group; and provided funding for medical writing assistance for the manuscript. All authors had full access to all study data; were involved in the planning, writing, and review of the manuscript; and had final responsibility for the decision to submit the manuscript for publication. Author Contributions Maureen Watt: conceptualization, data curation, methodology, supervision, validation, and writing – original draft, reviewing, and editing. Inmaculada Martinez-Saguer, Ricardo Zwiener, Mauricio Sarrazola, and Anete S. Grumach: investigation, methodology, and writing – original draft, reviewing, and editing. Ryan Murphy: data curation, formal analysis, methodology, validation, and writing – original draft, reviewing, and editing. Marie De La Cruz: conceptualization, methodology, and writing – original draft, reviewing, and editing.